MYC and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome: The present study may indicate an additional therapeutic application for c-Myc inhibitors in a subset of PACa patients that have a poor prognosis, and possibly in patients with neuroendocrine prostate cancer.